Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Cancer Lett. 2012 Feb 2;320(1):104–110. doi: 10.1016/j.canlet.2012.01.039

Figure 2. MTT assay of MDA-MB-231, MCF-7, and SK-BR-3 cells treated with drug combinations with dasatinib for 48 hours.

Figure 2

Drug combinations were administered in a 1:1 ratio. Percent proliferation was calculated relative to untreated controls. Data points represent averages from triplicates. Error bars indicate standard deviation.